Volver a Agenda
Session Chair(s)
Alan Hochberg
Principal Scientific Enablement Director, Scientific Enablement and Processes
Genentech, A Member of the Roche Group, United States
Learning Objective : Identify opportunities, limitations, and challenges of premarketing signal detection; Describe best practices for product-specific safety monitoring in ambulatory and institutional settings; Recognize various pharmacovigilance stakeholders, their motivations, and their individual advantages and disadvantages as providers of drug safety information.
Speaker(s)
Premarketing Signaling: The What's, Why's and How's
Michael J. Klepper, MD
Drug Safety Navigator, United States
President and Founder
Optimizing Product Specific Safety Monitoring
Stella Stergiopoulos, MPH, MS
EQRx, United States
Director, Health Economic and Outcomes Research
Who Should Do Safety Signal Detection and Why (or Why Not)?
Alan Hochberg
Genentech, A Member of the Roche Group, United States
Principal Scientific Enablement Director, Scientific Enablement and Processes
¿Tiene una cuenta?